Randomized Clinical Study of a Histamine H3 Receptor Antagonist for the Treatment of Adults with Attention-Deficit Hyperactivity Disorder

  title={Randomized Clinical Study of a Histamine H3 Receptor Antagonist for the Treatment of Adults with Attention-Deficit Hyperactivity Disorder},
  author={Richard H. Weisler and Gahan Pandina and Ella J. Daly and Kimberly L. Cooper and Cristiana Gassmann-Mayer},
  journal={CNS Drugs},
AbstractBackground: Psychostimulants, including methylphenidate and amphetamine preparations, are commonly prescribed for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. Histamine H3 receptors reside on non-histamine neurons and regulate other neurotransmitters (e.g. acetylcholine, noradrenaline [norepinephrine]) suggesting that H3 antagonists have the potential to improve attention and impulsivity. Research indicates that H3 receptor antagonists due to… 
Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions
A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia.
Neither dose of ABT-288 resulted in cognitive improvement in clinically stable adults with schizophrenia, however, an increased incidence of psychosis-related and sleep-related adverse events was associated with ABt-288.
Pitolisant and Other Histamine-3 Receptor Antagonists—An Update on Therapeutic Potentials and Clinical Prospects
Although limited clinical studies have been conducted on this new class of drugs, the reviewed literature showed promising results for future additions to the clinical indications of pitolisant, and the expansion of the list of approved drugs in this class for a variety of indications.
Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)
A review of the scientific literature and of unpublished/ongoing clinical trials to summarize the advances made in the last 10 years for the pharmacological treatment of ADHD found many pharmacological mechanisms beyond dopaminergic and noradrenergic ones have been investigated in patients.
Current Investigational Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder
The limitations of currently available medications including methylphenidates, amphetamines, atomoxetine, extended- release guanfacine and extended-release clonidine are considered, and drugs in development for the treatment of ADHD are examined.
Histaminergic system in brain disorders: lessons from the translational approach and future perspectives
The role of histaminergic system in brain disorders, as well as the effects of different histamine antagonists on animal models and humans, are summarized.
Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis
LDX has the largest effect size and has a promising potential for treating adults with ADHD, according to a meta-analysis of clinical trials conducted on adults diagnosed with ADHD.
Histamine H3R Antagonists: From Scaffold Hopping to Clinical Candidates
The histamine H3 receptor, belonging to the family of G-protein-coupled receptors, is predominantly expressed in the central nervous system (CNS), and playing a key role as actuator of neurotransmitter release for, e.g., dopamine, acetylcholine, noradrenaline, or serotonin.
The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders
Positive trends in several result measures suggest that medications that improve cognitive function, like MOD or R-MOD, may be beneficial for the treatment of substance use disorders in certain patient populations.


Efficacy of Methylphenidate for Adults with Attention-Deficit Hyperactivity Disorder
This study shows that methylphenidate improves ADHD symptoms in adults in a dose-dependent fashion, and appears to be reduced in patients with co-morbid SUD.
Safety of therapeutic methylphenidate in adults: a systematic review of the evidence
  • J. Godfrey
  • Psychology, Medicine
    Journal of psychopharmacology
  • 2009
There is little information on the long-term safety of methylphenidate in adults, although the number of serious adverse effects reported to regulatory authorities has, so far, been low.
Histamine H3 antagonists for treatment of cognitive deficits in CNS diseases.
The high interest level by several pharmaceutical companies in H(3) receptors as potential drug targets has produced rapid advancement in novel compound series with different properties, providing a variety of preclinical tools as well as advancing several candidates into clinical trials.
Efficacy and Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Dose-Escalation Study
In a dose escalation ranging from 36 to 108 mg/d, OROS methylphenidate is effective and well tolerated in the management of ADHD in adults.
The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders.
Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
The biological and chemical implications for developing H3 receptor antagonists and their therapeutic potential as disclosed through animal models of cognition, sleep, and obesity are described.
Meta-Analysis of the Efficacy of Methylphenidate for Treating Adult Attention-Deficit/Hyperactivity Disorder
Strong support is found for the assertion that MPH is efficacious for treating adult ADHD and provides further assurance to clinicians that the diagnosis of ADHD can be validly applied in adulthood.